Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

innovent biologics unspon ads ea rep 4 ord shs - IVBIY

IVBIY

Close Chg Chg %
22.96 -0.67 -2.90%

Open Market

22.29

-0.67 (2.90%)

Volume: 200.00

Last Updated:

Mar 31, 2025, 11:56 AM EDT

Trade Now

Company Overview: innovent biologics unspon ads ea rep 4 ord shs - IVBIY

IVBIY Key Data

Open

$22.29

 Day Range

22.29 - 22.29

52 Week Range

19.15 - 22.96

 Market Cap

$9.97B

Shares Outstanding

409.55M

 Public Float

N/A

Beta

-0.03

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

N/A

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

14.04

  

IVBIY Performance

No Data Available

IVBIY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Innovent Biologics Unspon Ads Ea Rep 4 Ord Shs - IVBIY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
662.04M 676.65M 875.94M 1.31B
Sales Growth
+18.88% +2.21% +29.45% +49.46%
Cost of Goods Sold (COGS) incl D&A
88.85M 138.26M 160.38M 209.84M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 31.75M 47.44M 54.35M
Depreciation
- 31.35M 41.10M 43.78M
Amortization of Intangibles
- 399.57K 6.33M 10.57M
COGS Growth
+58.16% +55.60% +16.00% +30.85%
Gross Income
573.19M 538.39M 715.57M 1.10B
Gross Income Growth
+14.47% -6.07% +32.91% +53.63%
Gross Profit Margin
+86.58% +79.57% +81.69% +83.97%
2021 2022 2023 2024 5-year trend
SG&A Expense
944.32M 935.22M 857.94M 1.08B
Research & Development
384.23M 426.39M 314.40M 372.54M
Other SG&A
560.09M 508.82M 543.54M 706.55M
SGA Growth
+79.60% -0.96% -8.26% +25.78%
Other Operating Expense
- - - -
-
Unusual Expense
(19.64M) (2.81M) (3.01M) (19.83M)
EBIT after Unusual Expense
(351.49M) (394.01M) (139.37M) 40.07M
Non Operating Income/Expense
(111.90M) 86.78M (8.24M) (35.90M)
Non-Operating Interest Income
- 23.53M 28.15M 63.91M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.69M 15.10M 13.92M 9.40M
Interest Expense Growth
-2.19% +55.94% -7.83% -32.47%
Gross Interest Expense
12.43M 17.40M 18.57M 9.40M
Interest Capitalized
- 2.74M 2.30M 4.65M
Pretax Income
(473.07M) (322.33M) (161.53M) (5.23M)
Pretax Income Growth
-280.25% +31.86% +49.89% +96.76%
Pretax Margin
-71.46% -47.64% -18.44% -0.40%
Income Tax
13.50M 1.31M (16.44M) 2.22M
Income Tax - Current - Domestic
- 13.50M 1.31M (16.44M)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(486.57M) (323.64M) (145.08M) (13.15M)
Minority Interest Expense
- - - -
-
Net Income
(486.57M) (323.64M) (145.08M) (13.15M)
Net Income Growth
-236.37% +33.49% +55.17% +90.94%
Net Margin Growth
-73.50% -47.83% -16.56% -1.00%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(486.57M) (323.64M) (145.08M) (13.15M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(486.57M) (323.64M) (145.08M) (13.15M)
EPS (Basic)
-1.3371 -0.8688 -0.3721 -0.0323
EPS (Basic) Growth
-213.58% +35.02% +57.17% +91.32%
Basic Shares Outstanding
363.90M 372.53M 389.91M 406.87M
EPS (Diluted)
-1.3371 -0.8688 -0.3721 -0.0323
EPS (Diluted) Growth
-213.58% +35.02% +57.17% +91.32%
Diluted Shares Outstanding
363.90M 372.53M 389.91M 406.87M
EBITDA
- (339.39M) (349.39M) (88.02M)
EBITDA Growth
- -2,577.14% -2.95% +74.81%
EBITDA Margin
- -51.26% -51.63% -10.05%

Innovent Biologics Unspon Ads Ea Rep 4 Ord Shs in the News